TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1744360

Group type: EXPERIMENTAL
Intervention: Commercial American cockroach extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: House dust extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-house cockroach whole body extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal extracts
Number of subjects: 0
Study: 7049347

Group type: EXPERIMENTAL
Intervention: AV
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 166
Study: 30272088

Group type: EXPERIMENTAL
Intervention: 5-year multifactorial intervention consisting of personal health education and contemporary drug treatments for dyslipidemia and hypertension.
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Shorter vacation time at baseline in the intervention group.
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: 5-year intervention improved total CVD risk by 46% in the intervention group.
Number of subjects: 1222
Study: 27421905

Group type: EXPERIMENTAL
Intervention: Simulation training in the ER
Number of subjects: 30
Study: 24638071

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 571

Group type: COMPARATOR
Intervention: Usual medical treatment
Number of subjects: 571
Study: 22622008

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m² per day, 5 days a week for 20 days])
Number of subjects: 200

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 200
Study: 20863761

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 504

Group type: COMPARATOR
Intervention: Pamidronate 30 mg
Number of subjects: 504
Study: 17656838

Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 33

Group type: COMPARATOR
Intervention: Trial and error learning
Number of subjects: 33
Study: 16134756

Group type: EXPERIMENTAL
Intervention: Valsartan (20-80 mg per day)
Number of subjects: 15
Study: 12270246

Group type: EXPERIMENTAL
Intervention: Nebuchamber (metal spacer)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Volumatic (plastic spacer)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1600 microg salbutamol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9562838

Group type: EXPERIMENTAL
Intervention: Alternative communication methods and active screening for illiteracy
Number of subjects: 0
Study: 7808837

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment, 0.5 mg/kg/d for 1 week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment
Number of subjects: 23
Study: 2483328

Group type: EXPERIMENTAL
Intervention: Fentanyl 6.5 micrograms/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oxymorphone 65 micrograms/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 39
Study: 1141135

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load
Number of subjects: 8

Group type: COMPARATOR
Intervention: No inspiratory resistive load (unloaded)
Number of subjects: 8
Study: 30985667

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with PapacarieMBlue
Number of subjects: 32

Group type: COMPARATOR
Intervention: Caries removal with a low-speed drill
Number of subjects: 32
Study: 28398846

Group type: EXPERIMENTAL
Intervention: TC6 (docetaxel and cyclophosphamide for six cycles)
Number of subjects: 4242

Group type: COMPARATOR
Intervention: TaxAC (docetaxel, doxorubicin, and cyclophosphamide or other standard AC and taxane combination regimens)
Number of subjects: 4242

Group type: EXPERIMENTAL
Intervention: TC6 plus bevacizumab (not included in the analysis)
Number of subjects: 4242
Study: 26331847

Group type: EXPERIMENTAL
Intervention: Emotional Availability Scales, Third Edition (Z. Biringen, J. Robinson, & R.N. Emde, 1998) during free play and teaching observations at home
Number of subjects: 226
Study: 24081946

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 14 days
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 21 days
Number of subjects: 71
Study: 20807262

Group type: EXPERIMENTAL
Intervention: Sulfo-carrabiose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of caffeine and sulfo-carrabiose
Number of subjects: 0
Study: 19904667

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 158
Study: 16913238

Group type: EXPERIMENTAL
Intervention: Oral sucrose administration
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1077
Study: 12362264

Group type: EXPERIMENTAL
Intervention: 3% erythromycin/5% benzoyl peroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.025% tretinoin/erythromycin 4%
Number of subjects: 0
Study: 11104215

Group type: EXPERIMENTAL
Intervention: Naloxone 30 microg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Naloxone 300 microg/kg
Number of subjects: 15
Study: 9302209

Group type: EXPERIMENTAL
Intervention: Cholestyramine + Methimazole (MMI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methimazole (MMI) alone
Number of subjects: 18
Study: 8179145

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trainee intubation
Number of subjects: 60
Study: 3297588

Group type: EXPERIMENTAL
Intervention: Destagnation plus radiotherapy
Number of subjects: 425

Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 425
Study: 29334878

Group type: EXPERIMENTAL
Intervention: IPS (Individual Placement and Support)
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2055
Study: 28274527

Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol (T+O) 2.5/5µg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol (T+O) 5/5µg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olodaterol (O) 5µg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol (T+O)
Number of subjects: 100
Study: 26906165

Group type: EXPERIMENTAL
Intervention: RTH258 4.5 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: RTH258 6.0 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: ranibizumab 0.5 mg
Number of subjects: 194
Study: 23765172

Group type: EXPERIMENTAL
Intervention: Standardized nutrition approach
Number of subjects: 223
Study: 21609286

Group type: EXPERIMENTAL
Intervention: Leucine-protein, high-carbohydrate nutrition (0.1/0.4/1.2/0.2 g·kg(‐1)·h(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric control (0.06/1.6/0.2 g·kg(‐1)·h(‐1))
Number of subjects: 10
Study: 18937813

Group type: EXPERIMENTAL
Intervention: Ocular pulse amplitude (OPA) measured with dynamic contour tonometry (DCT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Axial length (AL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Left ventricle ejection time (LVET)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mean IOP, AL, and LVET (multiple linear regression analysis)
Number of subjects: 29
Study: 16697231

Group type: EXPERIMENTAL
Intervention: Oral Lactobacillus rhamnosus GR‐1 (1 x 10(9)) and Lactobacillus reuteri RC‐14 (1 x 10(9))
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 125
Study: 15568329

Group type: EXPERIMENTAL
Intervention: P1 Medium supplemented with 20% SSS
Number of subjects: 349

Group type: COMPARATOR
Intervention: Cook Medium
Number of subjects: 349
Study: 11783604

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 41
Study: 9009113

Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 8

Group type: COMPARATOR
Intervention: Still water
Number of subjects: 8
Study: 8024295

Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler (half the normal dose)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Budesonide via Nebuhaler (normal dose)
Number of subjects: 241
Study: 3501538

Group type: COMPARATOR
Intervention: 5-fluorouracil (FUra)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (FUra) plus high-dose continuous-infusion folinic acid
Number of subjects: 50
Study: 31255546

Group type: EXPERIMENTAL
Intervention: Polyetheretherketone (Pk)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Titanium (T)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Polyetheretherketone with titanium base (Pkt)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Implant position
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Implant material
Number of subjects: 1
Study: 29128208

Group type: EXPERIMENTAL
Intervention: Whole pelvic radiation therapy (WPRT)
Number of subjects: 1861

Group type: COMPARATOR
Intervention: Prostate bed radiation therapy (PBRT)
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 1861

Group type: COMPARATOR
Intervention: No androgen deprivation therapy (No ADT)
Number of subjects: 1861

Group type: COMPARATOR
Intervention: WPRT vs PBRT
Number of subjects: 1861

Group type: COMPARATOR
Intervention: No ADT vs ADT
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Distant metastases (DM)
Number of subjects: 1861
Study: 27459349

Group type: EXPERIMENTAL
Intervention: Nurse-led multifactorial care with systematic comprehensive geriatric assessment and tailored interventions
Number of subjects: 2283

Group type: COMPARATOR
Intervention: Current primary care (control group)
Number of subjects: 2283

Group type: EXPERIMENTAL
Intervention: Nurse-led multifactorial care
Number of subjects: 2283
Study: 24224920

Group type: EXPERIMENTAL
Intervention: Platelet transfusions based on platelet mass
Number of subjects: 30

Group type: COMPARATOR
Intervention: Platelet transfusions based on platelet count
Number of subjects: 30
Study: 22352519

Group type: EXPERIMENTAL
Intervention: Natural variations in fundamental frequency (flattened or removed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limiting availability of speech envelope and temporal fine structure cues via noisy signal extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speech envelope
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speech information transmitted by the envelope
Number of subjects: 0
Study: 20466803

Group type: EXPERIMENTAL
Intervention: High-carbohydrate group (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-carbohydrate group (n = 8)
Number of subjects: 16
Study: 18663341

Group type: EXPERIMENTAL
Intervention: Protection cream containing antioxidant substances with high radical protection factor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15537673

Group type: EXPERIMENTAL
Intervention: Cortical thickness measurement in AD patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cortical thickness measurement in controls
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cortical thickness measurement over time
Number of subjects: 36
Study: 14511552

Group type: EXPERIMENTAL
Intervention: P. falciparum infections
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: P. vivax infections
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Severe malaria requiring intravenous quinine therapy
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Incidence of malarial infection
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Geometric mean parasite counts for P. falciparum
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Geometric mean parasite counts for P. vivax
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Prevalence of parasitaemia in the village
Number of subjects: 243
Study: 10710132

Group type: EXPERIMENTAL
Intervention: Smoking (cigarette)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study: 8648387

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy with mantle or mediastinal RT
Number of subjects: 60

Group type: COMPARATOR
Intervention: ABVD chemotherapy
Number of subjects: 60
Study: 8398189

Group type: EXPERIMENTAL
Intervention: Prophylactic digoxin
Number of subjects: 50

Group type: COMPARATOR
Intervention: No prophylactic digoxin (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 50
Study: 3950878

Group type: EXPERIMENTAL
Intervention: Ampicillin-Gentamicin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 123
Study: 28971727

Group type: EXPERIMENTAL
Intervention: DSL prescription
Number of subjects: 232

Group type: COMPARATOR
Intervention: NAL prescription
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both DSL and NAL prescriptions
Number of subjects: 232
Study: 27496577

Group type: EXPERIMENTAL
Intervention: Arthrocentesis and BTX‐A injections in the temporal and masseter muscles (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: BTX‐A injections in the temporal and masseter muscles only (Group B)
Number of subjects: 20
Study: 25918808

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 56
Study: 22746075

Group type: EXPERIMENTAL
Intervention: TNP laparostomy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 57
Study: 20405784

Group type: EXPERIMENTAL
Intervention: Parallel electrode orientation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Perpendicular electrode orientation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parallel and Perpendicular electrode orientations
Number of subjects: 10
Study: 18505783

Group type: EXPERIMENTAL
Intervention: Oral melphalan, prednisone, and thalidomide (MPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard melphalan and prednisone (MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thalidomide or bortezomib as salvage regimens in MP group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide or bortezomib as salvage regimens in MPT group
Number of subjects: 0
Study: 16015051

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0
Study: 12629058

Group type: EXPERIMENTAL
Intervention: Lenograstim 5 microg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Lenograstim 10 microg/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lenograstim 2 microg/kg
Number of subjects: 43
Study: 10537443

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg twice daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg twice daily) plus Loviride (100 mg 3 times daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8777105

Group type: EXPERIMENTAL
Intervention: Fuzzy group (n = 15) with minimal flow (0.5 litre min‐1) and fuzzy logic feedback control of gas concentrations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard group (n = 15) with low flow anaesthesia (1.2‐1.3 litre min‐1) and manual control of gas concentrations
Number of subjects: 30
Study: 2054076

Group type: EXPERIMENTAL
Intervention: GORE-TEX bags containing silver sulphadiazine cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polythene bags
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GORE-TEX bags
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GORE-TEX bags and Polythene bags
Number of subjects: 0
Study: 6423263

Group type: COMPARATOR
Intervention: Preoperative radiotherapy alone
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy combined with 5-fluorouracil
Number of subjects: 247
Study: 30620151

Group type: EXPERIMENTAL
Intervention: Experimental group (operant conditioning with rewards and punishments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random-control group (non-contingent rewards and punishments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colour-control group (no rewards or punishments)
Number of subjects: 0
Study: 29913015

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 116

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 116
Study: 27410169

Group type: EXPERIMENTAL
Intervention: Vacuum‐formed co‐polyester oral splints (Group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prefabricated oral splints with water‐filled elastic pads (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Michigan‐type hard splints (Group C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 36
Study: 25386778

Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not available)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (specific control details not available)
Number of subjects: 194
Study: 22587540

Group type: EXPERIMENTAL
Intervention: Scientifically determined nutrition strategy (S)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Self-chosen nutrition strategy (A)
Number of subjects: 18
Study: 19860749

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 20 mg (5 mg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine 80 mg (20 mg/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 60
Study: 17606957

Group type: EXPERIMENTAL
Intervention: Cystatin C level
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Serum creatinine concentration
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Iothalamate GFR
Number of subjects: 825
Study: 16525984

Group type: EXPERIMENTAL
Intervention: Bipolar sealer device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional electrocautery
Number of subjects: 50
Study: 12384409

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell (PBSC) transplantation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Bone marrow (BM) transplantation
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Chronic GVHD treatment
Number of subjects: 101
Study: 10439747

Group type: EXPERIMENTAL
Intervention: Liposomal PGE1 (0.15‐3.6 micrograms/kg) every 6 hours for up to 7 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7872852

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention provided to physicians
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (physicians who received the consultation letter after 12 months)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention
Number of subjects: 56
Study: 2087863

Group type: EXPERIMENTAL
Intervention: Training program (3-4 sessions per day, 5 days a week, intensity up to 1 W/kg body weight)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training program (specifically for EF less than 30%)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training program (for EF greater than 30%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 32111

Group type: EXPERIMENTAL
Intervention: Spring-loaded clip technique
Number of subjects: 599

Group type: COMPARATOR
Intervention: Tubal ring technique
Number of subjects: 599
Study: 30722062

Group type: EXPERIMENTAL
Intervention: menthol Tobacco Heating System (mTHS) 2.2
Number of subjects: 160

Group type: COMPARATOR
Intervention: menthol cigarettes (mCCs)
Number of subjects: 160

Group type: COMPARATOR
Intervention: smoking abstinence (SA)
Number of subjects: 160
Study: 31064236

Group type: EXPERIMENTAL
Intervention: Topical Platelet-rich plasma (PRP) applied twice a day for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gentamicin and betamethasone for the first 7 days, then hyaluronic acid gel for 12 weeks
Number of subjects: 50
Study: 26704712

Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (200 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (starch, 200 mg)
Number of subjects: 54
Study: 25010702

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Psychosocial Treatment as Usual (TAU)
Number of subjects: 20
Study: 23915854

Group type: EXPERIMENTAL
Intervention: Internet-based health management platform (HMP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 22000135

Group type: EXPERIMENTAL
Intervention: Antegrade cerebral perfusion (ACP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 74
Study: 19963099

Group type: EXPERIMENTAL
Intervention: Temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly (175/75)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Investigator's choice therapy
Number of subjects: 162
Study: 17407035

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 203

Group type: COMPARATOR
Intervention: Group C meningococcal conjugate vaccine
Number of subjects: 203
Study: 15523338

Group type: EXPERIMENTAL
Intervention: Axis Dental polishing system
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Brasseler polishing system
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Jelenko polishing system
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (autoglazed surface)
Number of subjects: 63
Study: 11233898

Group type: EXPERIMENTAL
Intervention: Preemptive or prophylactic lamivudine treatment (n=10)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salvage lamivudine treatment after hepatic dysfunction (n=6)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-lamivudine treated group (control group, n=25)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine treatment (n=3)
Number of subjects: 36
Study: 9780618

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS5MN) 20 mg bid (8.00 am and 3.00 pm) for 1 week (Group 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS5MN) 40 mg bid (8.00 am and 8.00 pm) for 1 week (Group 2)
Number of subjects: 10